We recorded 78 VC/PE transactions pertaining to the global life sciences sector for Dec 2020, aggregating to a sum of USD 4.5B.
USA recorded 46 transactions for with total investment of USD 2.1B. China reported investment of USD 1.9B over 14 VC/PE transactions.
China also reported 3 IPOs aggregating a fund raise of USD3.9B, and 9 cross border transactions involving in/out licensing deals and other forms of research partnerships.
For 2020, total venture capital investment in Lifesciences companies was ~USD40B, from over 700 transactions.
The top 5 VC / PE transactions for Dec’20 were:
- DXY, a Tencent-backed Chinese healthtech firm, secured $500 million in a new funding round led by growth-oriented private equity (PE) firm Trustbridge Partners. Tencent Investment and GL Ventures, the venture capital (VC) unit of Asia-focused PE major Hillhouse Capital, participated in the investment.
- Tencent and Asia-based growth capital asset manager Jeneration Capital jointly led an investment of nearly $305.3 million in the Chinese oncology medical service platform Medbanks.
- Tiger Global Management led a $225.5 million round in the Columbus, Ohio-based company, Olive, a startup that develops AI tools for hospital systems
- Nuance Pharma, a Chinese biopharma company focused on iron deficiency, pain management and respiratory, raised Series D financing amounting to $181 million
- US’s at-home testing company Everlywell raised a USD175m round, propelled by the Covid pandemic. The key investors in the round were BlackRock, The Chernin Group, Foresite Capital, Greenspring Associates, Lux Capital, Morningside Ventures, and Portfolia.